| Class 3 Device Recall Abbott | |
Date Initiated by Firm | February 01, 2024 |
Date Posted | February 26, 2024 |
Recall Status1 |
Open3, Classified |
Recall Number | Z-1189-2024 |
Recall Event ID |
93902 |
Product Classification |
Reagents, specific, analyte - Product Code MVU
|
Product | In-vitro diagnostic kits:
(1) Abbott Vysis LSI ATM (11q22.3) SpectrmOrange Probe, REF 01N33-020;
(2) Abbott Vysis PTEN/CEP 10 FISH Probe Kit, REF 04N62-020;
(3) Abbott Vysis TelVysion 1p SpectrumGreen Probe, REF 05J03-001;
(4) Abbott Vysis TelVysion 4P SpectrumGreen Probe, REF 05J03-004;
(5) Abbott Vysis TelVysion 22q SpectrumOrange Probe, REF 05J04-022; |
Code Information |
(1) REF 01N33-020 - GTIN 00884999000759, Lot #381411, Exp. 2024-09-22;
(2) REF 04N62-020 - GTIN 00884999009301, Lot #382133, Exp. 2024-05-25;
(3) REF 05J03-001 - GTIN 00884999009882, Lot #381111, Exp. 2024-06-17;
(4) REF 05J03-004 - GTIN 00884999009912, Lot #381102, Exp. 2024-06-17;
(5) REF 05J04-022 - GTIN 00884999010451, Lot #530242, Exp. 2024-03-28.
|
Recalling Firm/ Manufacturer |
Abbott Molecular, Inc. 1300 E Touhy Ave Des Plaines IL 60018-3315
|
For Additional Information Contact | Ray Bastian 224-361-7000 |
Manufacturer Reason for Recall | Products that were intended for export only which were not approved or registered in accordance with U.S. specifications were shipped to U.S. customers. |
FDA Determined Cause 2 | Process control |
Action | The recalling firm issued letters dated and issued on 2/1/2024 via FedEx priority overnight express mail. The letter explained the background, potential impact, and necessary actions to be taken and contained an appendix listing Impacted Abbott Products and an appendix listing CE products and similar US products. The actions to be taken were to destroy all remaining inventory of the impacted products and contact their local Abbott representative for replacements. If the product has been forwarded to other laboratories, the consignee is requested to inform them of the recall and have them take the necessary actions. The letter states that laboratories should follow internal procedures in regard to a lookback of results and a lookback should be considered if results have been released that are tied to performance claims. A Customer Reply Form was enclosed to acknowledge receipt of the letter. The consignee was to record the amount of affected product that was destroyed. |
Quantity in Commerce | 7 kits |
Distribution | US Nationwide distribution in the states of AL, CA, IL, MA, MD, MN, NY, and PA. |
Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes.
|
|
|
|